Remedial Magic of Dostarlimab in Endometrium Cancer
Journal: International Journal of Science and Research (IJSR) (Vol.11, No. 10)Publication Date: 2022-10-05
Authors : Mitushi Singh; Gorika Tomar; Isha Sharma; Prashant Mathur;
Page : 1106-1110
Keywords : Immunotherapy; Programmed cell death protein receptor; Endometrial cancer;
Abstract
Endometrial cancer can be cured if we can diagnosed it early, even after that 0.88 million cases were found in India with an incident rate of 105.5 per 100, 000 in women. Immunotherapy is one of the most effective and convenient method used in the treatment of cancer. It includes immune checkpoint inhibitors therapy, monoclonal antibody therapy for example anti-programmed cell death proteinPD-1 receptor monoclonal antibody (Dostarlimab), antigen T-cell therapy. Immunotherapy works on the cancer cells by making their progression decline and controls the growth of cells. In this review, we discussed the mechanism of Dostarlimab in the endometrial cancer mainly. We also discussed the different trials that were going out with the drug Dostarlimab and the pharmacokinetic and pharmacodynamic of the drug which helps in the better understanding of the drug in terms of its evolution after the large number of trials in humans and other living organism also.
Other Latest Articles
- Internal Factors Affecting Students' Preferences on Vocational Education in the Arts: A Survey in Indonesia
- The South-East Bulgarian Black Sea Coast as Destination for Mass Sea and / or Climate and Spa Tourism
- Parental Knowledge Levels, Attitudes, and Practices Regarding Childhood Vaccination: A Cross-Sectional Study in Riyadh City, Saudi Arabia
- Rough Statistical Convergence on Biquadratic Sequences
- A Rare Case Report of Late Onset Hemorrhagic Disease of Newborn
Last modified: 2025-09-22 21:31:24